Alteration of opioid peptide circadian rhythm in cancer patients
Barni, S.; Lissoni, P.; Rovelli, F.; Crispino, S.; Paolorossi, F.; Esposti, D.; Esposti, G.; Fraschini, F.; Tancini, G.
Tumori 74(3): 357-360
1988
ISSN/ISBN: 0300-8916 PMID: 2969639 Document Number: 308846
Endogenous opioid peptides have been seen to play a role in regulating immunity and tumor growth. This study was carried out to investigate opioid activity in human cancer. We evaluated by radioimmunoassay .beta.-endorphin plasma levels on blood samples collected at 9.00 a.m. from 121 cancer patients and 42 healthy subjects. In 22 cancer patients and in 12 controls, .beta.-endorphin circadian rhythm was also investigated. Finally, in 14 cancer patients and in 10 controls GH, PRL, FSH, LH and cortisol serum levels were measured after the administration of a metenkephalin analogue, FK 33-824 (0.3 mg i.v.). No significant differences were seen in .beta.-endorphin mean levels between cancer patients and normal subjects. Moreover, no differences were found between patients with or without metastases, nor between those with or without chronic pain. .beta.-Endorphin circadian rhythm appeared to be altered in 16/22 cancer patients, and anomalous hormonal responses to FK 33-824 were seen in 13/14 patients. This study shows an altered opioid activity in human neoplasms, whose clinical significance remains to be determined.